Success rates for product development strategies in new drug development
clinical trials, product development
While research has examined the likelihood that drugs progress across phases of clinical trials, no research to date has examined the types of product development strategies that are the most likely to be successful in clinical trials. This research seeks to identify the strategies that are most likely to reach the market—those generated using a novel product development strategy or strategies that combine a company's expertise with both drugs and indications, which we call combined experience strategies.
Original Publication Citation
Dahlin, Eric, Greg Nelson, Meagan Haynes,† and Francis Sargeant.† 2016. “Success Rates for Product Development Strategies in New Drug Development.” Journal of Clinical Pharmacy & Therapeutics 41:198-202
BYU ScholarsArchive Citation
Dahlin, Eric C.; Nelson, G. M.; Haynes, M.; and Sargeant, F., "Success rates for product development strategies in new drug development" (2016). All Faculty Publications. 2587.
Journal of Clinical Pharmacy and Therapeutics
© 2016 John Wiley & Sons Ltd